{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:10:16Z","timestamp":1775790616595,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.01526","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T11:51:06Z","timestamp":1546948266000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis"],"prefix":"10.3389","volume":"9","author":[{"given":"Jurgen","family":"Sota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Insalaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Alessio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Cattalini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Gallizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"La Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Pardeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alma Nunzia","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Sfriso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Gaggiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Bracaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"De Benedetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1177\/039463201102400402","article-title":"Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes.","volume":"24","author":"Cantarini","year":"2011","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.autrev.2016.07.004","article-title":"Systemic-onset juvenile idiopathic arthritis.","volume":"15","author":"Cimaz","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/archdischild-2016-311571","article-title":"Mortality rates are increased in patients with systemic juvenile idiopathic arthritis.","volume":"102","author":"Davies","year":"2017","journal-title":"Arch. Dis. Child."},{"key":"B4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s12098-017-2293-5","article-title":"Course, outcome and complications in children with systemic onset juvenile idiopathic arthritis.","volume":"84","author":"Dewoolkar","year":"2017","journal-title":"Indian J. Pediatr."},{"key":"B5","first-page":"668","article-title":"Efficacy and safety of canakinumab in patients with still\u2019s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.","volume":"36","author":"Feist","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1007\/s00296-011-2249-4","article-title":"Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA).","volume":"32","author":"Hedrich","year":"2012","journal-title":"Rheumatol. Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s12098-016-2060-z","article-title":"Systemic juvenile idiopathic arthritis: diagnosis and management.","volume":"83","author":"Kumar","year":"2016","journal-title":"Indian J. Pediatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/13543784.2017.1301929","article-title":"Investigational drugs for treatment of juvenile idiopathic arthritis.","volume":"26","author":"Mauro","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","article-title":"Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.","volume":"7","author":"Mellins","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2011-201060","article-title":"Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.","volume":"72","author":"Otten","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.berh.2018.02.002","article-title":"Systemic juvenile idiopathic arthritis: new insights into pathogenesis and cytokine directed therapies.","volume":"31","author":"Pardeo","year":"2017","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3899\/jrheum.141567","article-title":"Anakinra in systemic juvenile idiopathic arthritis: a single-center experience.","volume":"42","author":"Pardeo","year":"2015","journal-title":"J. Rheumatol."},{"key":"B17","first-page":"390","article-title":"International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.","volume":"31","author":"Petty","year":"2004","journal-title":"J. Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/1744666X.2017.1280396","article-title":"A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner.","volume":"13","author":"Rigante","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2018.067","article-title":"The broad-ranging panorama of systemic autoinflammatory disorders with specific focus on acute painful symptoms and hematologic manifestations in children.","volume":"10","author":"Rigante","year":"2018","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/acr.22087","article-title":"2013 update of the 2011 American college of rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.","volume":"65","author":"Ringold","year":"2013","journal-title":"Arthritis Care Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.","volume":"367","author":"Ruperto","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3899\/jrheum.090952","article-title":"Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.","volume":"36","author":"Russo","year":"2009","journal-title":"J. Rheumatol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4119-x","article-title":"Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study.","author":"Sota","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-12-13","article-title":"Treatment of juvenile idiopathic arthritis: a revolution in care.","volume":"12","author":"Stoll","year":"2014","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1136\/ard.2007.087130","article-title":"Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.","volume":"68","author":"Tynj\u00e4l\u00e4","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B28","first-page":"2071","article-title":"Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.","volume":"31","author":"Verbsky","year":"2004","journal-title":"J. Rheumatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01526\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T04:25:05Z","timestamp":1547180705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01526\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":28,"alternative-id":["10.3389\/fphar.2018.01526"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.01526","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,8]]},"article-number":"1526"}}